SEC Filing Analysis: BIO-TECHNE Corp (TECH)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director received a routine, pre-planned grant of common stock and stock options as part of their annual compensation.
• Market Impact: Negligible. This is a non-market transaction with minimal dilutive effect and does not signal a change in insider sentiment.

Company Information

Field	Value
Company	BIO-TECHNE Corp
Ticker Symbol	TECH
CIK	0000842023
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	BAUMGARTNER ROBERT V
CIK	0001258704
Title/Position	null
Relationship	Director

Transaction Details

This filing reports two grant transactions:

1. Common Stock Grant: An award of 1,640 shares of common stock.
2. Stock Option Grant: An award of 3,777 stock options with an exercise price of $60.96.

Field	Value (Common Stock Grant)
Form Type	4
Transaction Date	2025-10-30
Transaction Code	A (Award)
Security Type	Common Stock
Shares Involved	1,640
Price Per Share	$0.00
Total Value	$0
Shares Owned After	46,503
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.00%
Shares Transacted	1,640
% of Shares Outstanding	0.001%
Post-Transaction Ownership	46,503 shares (0.03% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction has no monetary value and is insignificant relative to BIO-TECHNE's $9.74 billion market capitalization.
• Ownership Concentration: The director's ownership stake remains very small at approximately 0.03% of total shares outstanding.
• Dilution Impact: The combined issuance of 1,640 shares and 3,777 options represents a potential future issuance of 5,417 shares, or approximately 0.0035% of shares outstanding. This is a negligible dilutive effect on current shareholders.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: These are standard compensation grants to a director, not open-market transactions. They do not reflect a discretionary investment decision by the insider.

Volume & Sentiment

• Expected Volume Impact: None. The transaction occurred outside the open market.
• Sentiment Indicator: Neutral. This type of filing is routine and does not typically influence market sentiment.

Additional Context

Transaction Notes

• The filing includes two separate awards: 1,640 shares of common stock and a grant of 3,777 stock options.
• The stock options have an exercise price of $60.96 and a 10-year expiration. Per a footnote, they vest on the earlier of October 30, 2026, or the date of the company's 2026 annual shareholders' meeting.